Cost minimisation analysis of fingolimod vs. natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis

Crespo, C.; Izquierdo, Guillermo; García-Ruiz, Antonio; Granell, Manuel; Brosa, Max

doi:10.1016/j.nrleng.2013.04.001

Cited by 3 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Geographically, of the 127 included studies, a majority were from the USA ( n = 29), followed by the UK ( n = 17) and Spain ( n = 10) [ 24 , 50 , 53 , 59 , 75 – 80 ]. HTA reports were mostly from Scotland ( n = 11) [ 29 , 30 , 81 – 89 ], followed by England ( n = 8) [ 90 – 97 ], and Canada ( n = 7) [ 28 , 98 – 103 ] (Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Overall, 73 studies and 25 HTA reports were cost-utility analyses, 16 studies were cost-effectiveness analyses, five studies and three HTAs were cost-minimization analyses [23][24][25][26][27][28][29][30], and six studies were budget impact analyses [31][32][33][34][35][36]. Furthermore, 17 studies comprised multiple economic evaluations [18,22,[37][38][39][40][41][42][43][44][45][46][47][48][49][50][51], six were cost-consequences analyses [52-57], two were cost-saving analyses [58, 59], one was a cost-benefit analysis [60], and one was a costoffset analysis [61].…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Geographically, of the 127 included studies, a majority were from the USA (n = 29), followed by the UK (n = 17) and Spain (n = 10) [24,50,53,59,[75][76][77][78][79][80]. HTA reports were mostly from Scotland (n = 11) [29,30,[81][82][83][84][85][86][87][88][89], followed by England (n = 8) [90][91][92][93][94][95][96][97], and Canada (n = 7) [28,[98][99][100][101][102][103] (Fig.…”

Section: Study Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review

Wiyani¹,

Badgujar

Khurana³

et al. 2021

Neurol Ther

View full text Add to dashboard Cite

Introduction: The introduction of diseasemodifying therapies (DMTs) for relapsing multiple sclerosis (RMS) over the last two decades has prompted the economic assessments of these treatments by reimbursement authorities. The aim of this systematic literature review was to evaluate the modeling approach and data sources used in economic evaluations of DMTs for RMS, identify differences and similarities, and explore how economic evaluation models have evolved over time. Methods: MEDLINEÒ, EmbaseÒ, and EBM Reviews databases were searched using OvidÒ Platform from database inception on 25 December 2019 and subsequently updated on 17 February 2021. In addition, health technology assessment agency websites, key conference proceedings, and gray literature from relevant

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review

Wiyani¹,

Badgujar

Khurana³

et al. 2021

Neurol Ther

View full text Add to dashboard Cite

show abstract

“…Two potentially attractive candidates are Zytiga and Gilenya (Figure 5 B), both of which bear structural resemblance to natural metabolites and are prohibitively expensive, with an estimated annual cost of $40000 per patient. 142 , 143 …”

Section: Future Perspectivesmentioning

confidence: 99%

“…Examples of such reactions include metal-catalyzed cross coupling transformations and olefin metathesis, reactions for which efficient protein catalysts are not presently available. − The identification of enzymes for these reactions, which are heavily used in pharmaceutical development, could facilitate the design of metabolic pathways for the microbial production of drugs. Two potentially attractive candidates are Zytiga and Gilenya (Figure B), both of which bear structural resemblance to natural metabolites and are prohibitively expensive, with an estimated annual cost of $40000 per patient. , …”

Section: Future Perspectivesmentioning

confidence: 99%

Enzyme Recruitment and Its Role in Metabolic Expansion

Schulenburg

Miller

2014

Biochemistry

View full text Add to dashboard Cite

Although more than 109 years have passed since the existence of the last universal common ancestor, proteins have yet to reach the limits of divergence. As a result, metabolic complexity is ever expanding. Identifying and understanding the mechanisms that drive and limit the divergence of protein sequence space impact not only evolutionary biologists investigating molecular evolution but also synthetic biologists seeking to design useful catalysts and engineer novel metabolic pathways. Investigations over the past 50 years indicate that the recruitment of enzymes for new functions is a key event in the acquisition of new metabolic capacity. In this review, we outline the genetic mechanisms that enable recruitment and summarize the present state of knowledge regarding the functional characteristics of extant catalysts that facilitate recruitment. We also highlight recent examples of enzyme recruitment, both from the historical record provided by phylogenetics and from enzyme evolution experiments. We conclude with a look to the future, which promises fruitful consequences from the convergence of molecular evolutionary theory, laboratory-directed evolution, and synthetic biology.

show abstract